Summary:
Pacific Research Partners is conducting a research study for the Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Qualified Participants Must:
• Have type 1 or type 2 diabetes treated with insulin whose LDL-C levels are not adequately controlled with maximally tolerated lipid-modifying therapy
•
Have a LDL-C of 70 mg/dL or greater
•
Be 18 years of age or older
•
Have Glycosylated hemoglobin (HbA1c) less than 10%
•
Have a history of cardiovascular disease (including CHD and/or CHD risk equivalents) and/or at least one additional cardiovascular risk factor
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.